Alliqua Inc. (ALQA) Given Buy Rating at HC Wainwright
ALQA has been the topic of several other research reports. Chardan Capital restated a buy rating on shares of Alliqua in a report on Sunday, July 10th. Zacks Investment Research downgraded Alliqua from a buy rating to a hold rating in a report on Friday, August 12th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of Buy and an average target price of $2.50.
Alliqua (NASDAQ:ALQA) traded up 0.581% during midday trading on Friday, hitting $0.865. 107,517 shares of the company traded hands. Alliqua has a 12-month low of $0.70 and a 12-month high of $3.82. The stock has a 50 day moving average price of $0.90 and a 200-day moving average price of $1.00. The company’s market cap is $25.67 million.
Alliqua (NASDAQ:ALQA) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.32. The firm had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.38 million. Alliqua had a negative return on equity of 53.07% and a negative net margin of 73.41%. Analysts expect that Alliqua will post ($0.72) EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in ALQA. US Bancorp DE boosted its position in Alliqua by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock valued at $204,000 after buying an additional 41,732 shares during the period. Vanguard Group Inc. boosted its position in Alliqua by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock valued at $587,000 after buying an additional 5,780 shares during the period. Suffolk Capital Management LLC boosted its position in Alliqua by 18.0% in the second quarter. Suffolk Capital Management LLC now owns 1,206,127 shares of the company’s stock valued at $1,351,000 after buying an additional 184,274 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Alliqua by 589.0% in the first quarter. Renaissance Technologies LLC now owns 137,800 shares of the company’s stock valued at $113,000 after buying an additional 117,800 shares during the period. 29.89% of the stock is currently owned by institutional investors.
Alliqua Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Inc. and related companies with MarketBeat.com's FREE daily email newsletter.